| P2093 | author name string | H-J Kim | |
| | T S Kim | |
| | Y-K Kim | |
| | T-H Lee | |
| | J H Song | |
| | W-S Min | |
| | S Y Hwang | |
| | S H Kweon | |
| P2860 | cites work | The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines | Q28240878 |
| | Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity | Q28577441 |
| | MethPrimer: designing primers for methylation PCRs | Q29618664 |
| | Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy | Q33236292 |
| | ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia | Q33251273 |
| | Acute myeloid leukemia | Q33741270 |
| | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 |
| | DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. | Q34433577 |
| | Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness | Q34715623 |
| | All tangled up: how cells direct, manage and exploit topoisomerase function | Q35154537 |
| | Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. | Q35865072 |
| | Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies | Q37935016 |
| | Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2. | Q39850081 |
| | Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells | Q39854262 |
| | Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. | Q39872553 |
| | Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells | Q39996238 |
| | Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia | Q41045806 |
| | Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance | Q41150940 |
| | Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome | Q41443225 |
| | Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells | Q41669786 |
| | Anthracyclines in haematology: preclinical studies, toxicity and delivery systems | Q41711763 |
| | The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia | Q42725619 |
| | Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia | Q44453872 |
| | Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. | Q44489089 |
| | 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine | Q44890934 |
| | Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations | Q45083309 |
| | SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. | Q46003074 |
| | Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia | Q46172925 |
| | Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis | Q46181718 |
| | Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients. | Q53418393 |
| | Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. | Q53453350 |
| | Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. | Q53879864 |
| | P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival; Malignancy | Q74000805 |
| | Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias | Q77620578 |
| | P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival | Q87912909 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 108-115 | |
| P577 | publication date | 2012-05-24 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia | |
| P478 | volume | 107 | |